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Abstract
Background: Proliferative glomerulonephritis with monoclonal IgG deposits (PGNMID) is a form of renal
involvement by monoclonal IgG deposits that was found in mesangial, subendothelial or subepithelial regions. The
distribution of glomerular deposits was completely different from that in monoclonal immunoglobulin deposition
disease. PGNMID is reported to be rarely associated with a hematological malignancy. Previously, only five cases of
PGNMID with multiple myeloma have been reported. However, the pathogenic relationship between PGNMID and
multiple myeloma was unclear because a detailed description was not provided. We report that a patient with
PGNMID associated with multiple myeloma was treated with bortezomib and dexamethasone and underwent the
second renal biopsy after treatment, showing that chemotherapy was effective for PGNMID clinically and
pathologically.
Case presentation: A 75-year-old man presented with progressive leg edema, had nephrotic range proteinuria,
hypoalbuminemia, moderate renal failure, and occult blood in his urine. Electrophoresis results showed serum and
urinary monoclonal spikes of IgGκ type immunoglobulin. A renal biopsy specimen showed lobular mesangial
proliferation with mesangiolysis, glomerular micro-aneurysm, and endocapillary hypercellularity.
Immunofluorescence results revealed strong granular capillary and mesangial staining for IgG1, C3 and κ light chain
in glomeruli without tubular deposits of any immunoglobulin. Electron microscopy also showed dense granular
deposits in subendothelial and mesangial areas. PGNMID associated with multiple myeloma (IgGκ type) was
diagnosed on the basis of a subsequent bone marrow examination. Bortezomib and dexamethasone therapy
significantly reduced proteinuria and elevated serum albumin level. Eight months later, the second renal biopsy
showed no active lesions and that the IgG1 and κ light chain deposits had drastically disappeared.
Conclusions: This is the first case of PGNMID with multiple myeloma successfully treated with bortezomib and
dexamethasone in which comparative renal biopsies were performed before and after treatment. Our findings
suggest the pathogenesis of PGNMID and therapeutic options for PGNMID.
Keywords: Proliferative glomerulonephritis with monoclonal IgG deposits (PGNMID), Multiple myeloma,
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Background
Nasr et al. recently described proliferative glomerulo-
nephritis with monoclonal IgG deposits (PGNMID) as a
novel form of glomerulonephritis that was positive for
the deposition of a single IgG subclass and a single light
chain isotype in mesangial, subendothelial, or subepithe-
lial regions [1]. On electron microscopy (EM) analysis,
these deposits were non-organized, granular, and similar
to those found in monoclonal immunoglobulin depos-
ition disease (MIDD). However, the distribution of glom-
erular deposits, which mimicked the deposits that occur
with ordinary immune-complex glomerulonephritis, was
completely different from that in MIDD [2].
The pathogenesis of PGNMID remains unknown.
However, PGNMID recurrence in renal allograft patients
suggests that this disease is caused by monoclonal im-
munoglobulin or other pathogenic factors circulating in
the serum [3–5]. In 30% of PGNMID cases, there is a
monoclonal component in serum [2]. However,
PGNMID is rarely associated with a hematological ma-
lignancy [2]. Including our case, only six cases of
PGNMID with multiple myeloma (MM) have been re-
ported [2, 6–8]. In four previous cases, the pathogenic
relationship between PGNMID and MM was unclear be-
cause a detailed description was not provided [2, 6, 7].
The other case with PGNMID complicated with MM
was treated with bortezomib and dexamethasone (BD)
therapy and her renal function improved after initiating
treatment for MM, though they did not examine second
renal biopsy after treatment [8].
Here, we describe a patient with PGNMID associated
with MM, for which BD therapy improved PGNMID,
comparing two renal biopsies obtained before and after
chemotherapy for MM.
Case presentation
A 75-year-old Japanese man with a history of hyperten-
sion, angina pectoris, and colon cancer presented at a
local hospital with progressive fatigue. His laboratory
test results showed serum albumin of 3.3 g/dL,
hemoglobin of 8.0 g/dL, urine protein of 4+, and nega-
tive urinalysis for occult blood. Three months later, he
presented with leg edema and loss of appetite and was
referred to our hospital. He had nephrotic range protein-
uria (6.0 g/g), hypoalbuminemia (albumin of 2.8 g/dL),
an elevated serum creatinine level (1.1 mg/dL), and urin-
alysis showed 30-49 red blood cells per high-power field
without cellular casts. Decreased levels of serum IgM
(14 mg/dL) and IgA (60 mg/dL) compared with a
normal IgG level (1202 mg/dL) suggested plasma cell
dyscrasia.
Protein electrophoresis showed monoclonal spikes
(IgGκ type) in both his serum and urine. A serum cryo-
globulin test was negative. An abdominal ultrasound
examination showed normal renal size and loss of corti-
comedullary differentiation in both kidneys. A renal bi-
opsy specimen (Fig. 1A), which contained 24 glomeruli
and 4 were sclerotic, showed lobular mesangial prolifera-
tion and expansion with mesangiolysis, glomerular
micro-aneurysm, and endocapillary hypercellularity. The
glomerular proliferative changes were global and almost
all glomeruli showed similar pattern. Duplication of
glomerular basement membrane was also observed.
Congo red staining was negative. Tubulointerstitial scar-
ring involved 30% of the renal cortex. No significant
interstitial inflammation was observed. Arteriosclerosis
was severe.
In the immunofluorescence studies, the manufactures
and dilutions of antibodies were as follows: IgG (MP Bio-
medicals, Santa Ana, CA, USA; dilution 1:400), IgA (MP
Biomedicals; dilution 1:200), IgM (MP Biomedicals; dilu-
tion 1:100), C3 (MP Biomedicals; dilution 1:200), C1q
(MP Biomedicals; dilution 1:50), IgG1, 2, 3, and 4
(Thermo Fisher Scientific, Waltham, MA, USA; dilution
1:200), κ and λ (SouthernBiotech, Birmingham, AL, USA;
dilution 1:50). Results showed glomeruli with granular ca-
pillary and mesangial staining for IgG (2+), C1q (1+), and
C3 (2+) and light chain isotype restriction limited to κ;
however, there were no tubular deposits. Staining for IgG
subclasses was positive for IgG1 only, and negative for
IgG2, IgG3, and IgG4. Electron-dense deposits in the sub-
endothelial and mesangial areas exhibited granular texture
and did not have fibrillary appearance. A bone marrow
examination revealed 17% IgGκ-positive monoclonal
plasma cells and confirmed a diagnosis of PGNMID asso-
ciated with MM (IgGκ type).
After his first kidney biopsy but before his diagnosis of
MM, this patient received methyl-prednisolone pulse
therapy for 2 days. After his diagnosis of MM, he was
started on weekly BD therapy (bortezomib at 1.3 mg/
m2/week, dexamethasone at 20 mg/week, 4-week treat-
ment per cycle). Prior to initiating BD therapy, his serum
albumin was 2.7 g/dL, creatinine was 1.52 mg/dL, κ/λ
ratio was >186, and urinalysis showed 12.3 g/g of protein
and 2+ occult blood. After the first BD course, labora-
tory test results improved remarkably, with serum albu-
min of 3.2 g/dL, creatinine of 1.42 mg/dL, κ/λ ratio of
5.09, and urine protein of 2.16 g/g. After the fourth
course of BD therapy, serum albumin was 3.6 g/dL, cre-
atinine was 1.00 mg/dL, κ/λ ratio was 1.10, and urinaly-
sis showed 0.25 g/g protein without occult blood
(Fig. 2). This patient underwent four cycles of BD ther-
apy followed by bortezomib maintenance therapy
(1.3 mg/m2, biweekly). No adverse effects were observed
and the laboratory results were stable.
A second renal biopsy was performed 8 months after
initiating BD therapy (Fig. 1B). The biopsy specimen
contained 26 glomeruli and 6 were sclerosed. Although
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renal biopsy results still showed the duplication of
glomerular basement membrane, mesangial matrix ex-
pansion, and weak deposition of C3 in mesangial
areas, there were no active lesions of mesangiolysis,
glomerular micro-aneurysm, and endocapillary hyper-
cellularity and no deposits of IgG and κ light chain.
The tubulointerstitial scarring was observed in 30% of
the renal cortex. There was no significant interstitial
inflammation. Arteriosclerosis was severe. An EM
examination also showed no electron-dense deposits
in a glomerulus. Our findings showed that BD ther-
apy had eliminated the pathogenic monoclonal pro-
tein in his serum and had reversed the renal damage
associated with PGNMID.
A B
Fig. 1 Renal biopsy histological features of PGNMID associated with multiple myeloma. First renal biopsy (a-k). a Periodic acid-Schiff (PAS)
staining: renal histopathology showed lobular glomeruli with mesangial expansion and cell proliferation complicated with acute lesions, such as
mesangiolysis, ×200. b Hematoxylin and eosin (HE) staining: glomerular micro-aneurysm and endocapillary hypercellularity, ×400. c Periodic acid
methenamine silver (PAM) staining: duplication of glomerular basement membrane (an arrow) and mesangiolysis (an arrow head) was observed,
×1000. Congo red staining was negative (not shown). d Immunoglobulin G (IgG), e immunoglobulin G1 (IgG1), and f kappa immunostaining were
detected on capillary walls and mesangial areas. (g) Lambda immunostaining was negative. h C3 immunofluorescence was positive (2+) on
capillary walls, and (i) C1q was also weakly positive (1+) on some capillary walls. No positive immunofluorescence was found in tubular basement
membranes. Staining for IgM and IgA was negative (not shown). IgG subclass analysis was positive for IgG1 only. IgG2, IgG3, and IgG4 were
negative (not shown). EM (j) low-power and (k) high-power fields showed that electron-dense deposits in the subendothelial and mesangial
areas exhibited a granular texture without a fibrillary appearance. Second renal biopsy (l-v). l Glomeruli showed less of an increase in mesangial
matrix in the first renal biopsy and no mesangiolysis or micro-aneurysms with PAS staining, ×100. m A glomerulus showed no endocapillary
hypercellularity with HE staining, ×400. n A glomerulus still had partial duplication of the glomerular basement membrane with PAM staining,
×1000. o IgG, (p) IgG1, (q) kappa, and (r) lambda immunofluorescence results were negative. (s) C3 immunofluorescence was weakly positive in a
mesangial area. (t) No deposition of C1q. EM (u) low-power and (v) high-power fields showed no electron-dense deposits
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Discussion
This report describes the case of a 75-year-old man
with nephrotic syndrome, who was diagnosed with
PGNMID associated with IgGκ type MM and success-
fully treated with BD therapy. In a renal biopsy after
this treatment, active lesions and IgGκ deposits in the
kidney had disappeared. PGNMID had remitted both
clinically and pathologically after serum IgGκ mono-
clonal proteins had disappeared. Taken together, our
findings suggest that MM had caused this patient’s
PGNMID.
In a case series of PGNMID reported by Nasr et al., only
1 of 37 had MM for several years and received stem cell
transplantation (SCT), although the details were not re-
ported [2]. Guiard et al. reported two cases of non-
cryoglobulinemic glomerulonephritis with monoclonal
immunoglobulin deposits complicated with MM [6]. One
patient was finally treated with thalidomide and cortico-
steroid, who developed end-stage renal disease. One was
diagnosed as having MM 81 months after renal presenta-
tion, which may suggest that multiple myeloma had not
evoked PGNMID. Redondo-Pachón et al. reported the de-
tails of a case of PGNMID with MM that was refractory
to treatment [7]. In that case, the types of immunoglobu-
lin in the myeloma cells and kidneys were not identical,
suggesting that the PGNMID was not related to MM. Re-
cently, Watanabe et al. have shown that a patient with
PGNMID complicated with MM was treated with BD
therapy and achieved a partial response with decreased
serum monoclonal protein and improved renal function
[8]. Although they did not examine renal histology after
treatment, immunofluorescence with IgG subclasses and
electron microscopic analysis of a glomerulus, the re-
sponse for the BD therapy was consistent with our case
that the patient reduced proteinuria and elevated serum
albumin level after the first BD course.
Monoclonal gammopathy of undetermined signifi-
cance (MGUS) is a condition characterized by the pres-
ence of monoclonal gammopathy without end organ
damage [9]. There are two ways by which MGUS transi-
tions to a malignant and symptomatic condition: (1)
somatic genetic abnormalities occur in tumor cells,
which results in MM; and (2) the clone produces a pro-
tein with an altered conformation, which causes progres-
sive organ dysfunction and conditions like light-chain
amyloidosis, MIDD, and cryoglobulinemia [10].
For patients with MM, 12-30% developed primary
amyloidosis, although the treatment of primary amyloid-
osis was difficult at the time of melphalan and prednis-
one therapy [11, 12]. Only a minority of patients treated
with this regimen responded and their median survival
was 12 to 18 months [13, 14]. This therapy had
remained unchanged for two decades until SCT was in-
troduced. After SCT with high-dose melphalan was
found to be effective for MM, the same regimen was also
used for primary amyloidosis. A recent report stated that
the median survival time was 4.6 years for patients
treated with SCT and high-dose melphalan [15]. Using
chemotherapy for myeloma during the management of
primary amyloidosis is logical, as it may rapidly eradicate
amyloidogenic light chains that are produced by a clonal
plasma cell population; this is also true for treating
MIDD [16–18].
Guiard et al. used rituximab to treat non-
cryoglobulinemic glomerulonephritis with monoclonal im-
munoglobulin deposits and without a hematologic malig-
nancy [6]. Rituximab was used in combination with other
chemotherapy regimens for two patients with low-grade
lymphoma and alone for five patients with no malignancy.
In five patients, complete remission of nephrotic syndrome
was achieved. The excellent results obtained with rituximab
therapy are very encouraging as compared with the results
Fig. 2 Clinical course. After initiating prednisolone therapy, this patient underwent four cycles of BD therapy (bortezomib at 1.3 mg/m2/week,
and dexamethasone at 20 mg/week), followed by bortezomib maintenance therapy (1.3 mg/m2, biweekly). The κ/λ ratio, urinary protein (UP), and
eGFR (calculated using equations for Japanese [26]) results are shown over the course of treatment
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obtained using corticosteroids alone or alkylating agent-
based regimens; this suggests that B-cell regulation can
ameliorate renal changes in PGNMID.
All patients who present with a well-defined severe
hematologic malignancy, such as MM or high-grade non-
Hodgkin lymphoma, must be treated according to stand-
ard chemotherapy protocols, which often include newly
introduced drugs, such as thalidomide, bortezomib, and
rituximab [19–21]. If a treatment achieves a hematologic
remission and suppresses circulating monoclonal immu-
noglobulins, then the renal complications caused by a
hematologic malignancy, including PGNMID, may dis-
appear, as was observed in our case. In contrast, plasma
cell dyscrasia or lymphoproliferative disorders can be in-
volved in the pathogenesis of PGNMID with monoclonal
gammopathy, similar to their involvement in MIDD and
light chain amyloidosis. As Guiard et al. demonstrated [6],
a specific treatment for MM or lymphoma, such as with
bortezomib and rituximab, may also be an effective treat-
ment for PGNMID without an overt malignancy [22].
There is still debate about the desirable strategy of the
second biopsy in kidney diseases, especially in lupus neph-
ritis [23–25]. In the renal diseases related to monoclonal
immunoglobulins, however, there has been no report dis-
cussing the clinical strategy of repeat biopsy. In the
present case, the 2nd biopsy pathologically showed
amendment in active lesions such as endocapillary hyper-
cellularity and mesangiolysis, reflecting the amendable ef-
fect of bortezomib and dexamethasone on histological
damages triggered by monoclonal immunoglobulins.
Therefore, the current case provides the first evidence that
monoclonal immunoglobulin-associated PGNMID can be
cured pathologically by eliminating the abnormal clonal
proliferation of B-cells or plasma cells. To circumvent the
potential risk related to the biopsy procedure, the
improved histological features can be inferred from the
improved laboratory test including serum albumin,
creatinine, κ/λ ratio and urine protein.
Conclusions
We have described a patient with PGNMID that was as-
sociated with MM and who was successfully treated with
BD therapy, which sheds some light for unraveling the
mechanism underlying PGNMID. Further studies are
necessary to determine whether PGNMID, particularly
with monoclonal gammopathy suggestive of plasma cell
dyscrasia, should be treated with the specific chemother-
apy used to treat MM.
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